Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
- PMID: 35131314
- DOI: 10.1016/j.ejphar.2022.174800
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Abstract
Neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, are characterized by the progressive loss of neuronal cells, resulting in different clinical symptoms according to the affected brain region. Although there are drugs available for the treatment of these diseases, they present relatively low efficacy and are not capable of modifying the course of the disease or stopping its progression. In the field of drug development, drug repurposing could be an interesting strategy to search new therapeutic options against neurodegenerative diseases, since it involves lower costs and time for development. In this review, we discuss the search of new treatments for Alzheimer's and Parkinson's disease through drug repurposing. A focus was given to drugs that modulate neuroinflammation, since it represents a common point among neurodegenerative diseases and has been explored as a target for drug action.
Keywords: Alzheimer; Antidiabetics; Immunomodulators; Non-steroidal anti-inflammatory drugs; Parkinson; Statins.
Copyright © 2022 Elsevier B.V. All rights reserved.
Similar articles
-
Repurposing GLP1 agonists for neurodegenerative diseases.Int Rev Neurobiol. 2020;155:91-112. doi: 10.1016/bs.irn.2020.02.007. Epub 2020 Aug 11. Int Rev Neurobiol. 2020. PMID: 32854860 Review.
-
New therapeutic strategy for Parkinson's and Alzheimer's disease.Curr Med Chem. 2010;17(25):2764-74. doi: 10.2174/092986710791859324. Curr Med Chem. 2010. PMID: 20586718 Review.
-
Repurposing of Copper(II)-chelating Drugs for the Treatment of Neurodegenerative Diseases.Curr Med Chem. 2018 Feb 12;25(4):525-539. doi: 10.2174/0929867324666170518094404. Curr Med Chem. 2018. PMID: 28521682 Review.
-
Antiapoptotic drugs: a therapautic strategy for the prevention of neurodegenerative diseases.Curr Pharm Des. 2011;17(3):230-45. doi: 10.2174/138161211795049732. Curr Pharm Des. 2011. PMID: 21348832 Review.
-
Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis.Expert Opin Investig Drugs. 2012 Sep;21(9):1267-308. doi: 10.1517/13543784.2012.703178. Epub 2012 Jun 28. Expert Opin Investig Drugs. 2012. PMID: 22741814 Review.
Cited by
-
Pazopanib alleviates neuroinflammation and protects dopaminergic neurons in LPS-stimulated mouse model by inhibiting MEK4-JNK-AP-1 pathway.Acta Pharmacol Sin. 2023 Jun;44(6):1135-1148. doi: 10.1038/s41401-022-01030-1. Epub 2022 Dec 19. Acta Pharmacol Sin. 2023. PMID: 36536076 Free PMC article.
-
LRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease.Int J Mol Sci. 2025 Feb 27;26(5):2093. doi: 10.3390/ijms26052093. Int J Mol Sci. 2025. PMID: 40076730 Free PMC article. Review.
-
Water-Soluble Ginseng Oligosaccharides Prevent Scopolamine-Induced Cholinergic Dysfunction and Inflammatory Cytokine Overexpression.Cell Biochem Biophys. 2025 Jun;83(2):2511-2518. doi: 10.1007/s12013-024-01660-8. Epub 2025 Jan 3. Cell Biochem Biophys. 2025. PMID: 39751741
-
Dose-Effect Determination of a Neuroprotector Fraction Standardized in Coumarins of Tagetes lucida and Bioavailability.Pharmaceutics. 2023 Mar 17;15(3):967. doi: 10.3390/pharmaceutics15030967. Pharmaceutics. 2023. PMID: 36986828 Free PMC article.
-
Cannabidiol inhibits neuroinflammatory responses and circuit-associated synaptic loss following damage to a songbird vocal pre-motor cortical-like region.Sci Rep. 2023 May 16;13(1):7907. doi: 10.1038/s41598-023-34924-z. Sci Rep. 2023. PMID: 37193782 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical